Apogee Therapeutics, Inc. Common Stock (APGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has a cash flow conversion efficiency ratio of -0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.69 Million) by net assets ($903.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apogee Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read APGE liabilities breakdown for a breakdown of total debt and financial obligations.
Apogee Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Delek Group
TA:DLEKG
|
-0.127x |
|
Sonoco Products Company
NYSE:SON
|
0.088x |
|
Teleflex Incorporated
NYSE:TFX
|
0.049x |
|
ChampionX Corporation
NASDAQ:CHX
|
0.035x |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
0.083x |
|
Outfront Media Inc
NYSE:OUT
|
0.161x |
|
Hess Midstream Partners LP
NYSE:HESM
|
0.607x |
|
Cochin Shipyard Limited
NSE:COCHINSHIP
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Apogee Therapeutics, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $903.88 Million | $-227.45 Million | -0.252x | -5.37% |
| 2024-12-31 | $716.79 Million | $-171.17 Million | -0.239x | -21.35% |
| 2023-12-31 | $379.91 Million | $-74.76 Million | -0.197x | -70.20% |
| 2022-12-31 | $142.07 Million | $-16.43 Million | -0.116x | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more